RecruitingNCT07484945
Multiomics Approach in Adult Patients With Phenylketonuria
Studying Disorder of phenylalanine metabolism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Tours
- Principal Investigator
- Yannick MOUPATAM-NGAMBY-ADRIAASEN, SirUniversity, Tours
- Enrollment
- 149 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2028
Study locations (15)
- University hospital, Angers, France
- University hospital, Bordeaux, France
- University hospital, Brest, France
- University hospital, Dijon, France
- University hospital, Grenoble, France
- University hospital, Lille, France
- Civil Hospitals, Lyon, France
- Conception hospital, Marseille, France
- University hospital, Nancy, France
- University hospital, Nantes, France
- Necker hospital, Paris, France
- University hospital, Rennes, France
- University hospital, Saint-Etienne, France
- University hospital, Toulouse, France
- university hospital, Tours, Tours, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07484945 on ClinicalTrials.govOther trials for Disorder of phenylalanine metabolism
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07220265Impact of Phenylalanine Elevations on Brain and Cognition in Adult PKU CarriersUniversity of Missouri-Columbia
- RECRUITINGPHASE3NCT06628128A Study to Evaluate the Long-Term Safety and Efficacy of JNT-517 in Participants With PhenylketonuriaOtsuka Pharmaceutical Development & Commercialization, Inc.
- RECRUITINGNANCT05579548A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and BreastfeedingBioMarin Pharmaceutical
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04480567AAV Gene Therapy Study for Subjects with PKUBioMarin Pharmaceutical